VistaGen Therapeutics, Inc. Gross Margin

Gross Margin of VTGN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Gross Margin growth rates and interactive chart. Gross profit margin shows the percentage of revenue that exceeds a company's costs of goods sold. It illustrates how well a company is generating revenue from the costs involved in producing their products and services. The higher the margin, the more effective the company's management is in generating revenue for each dollar of cost. Gross profit margin is calculated by subtracting the cost of goods sold from total revenue for the period and dividing that number by revenue. If a company has $200 million in revenue and $80 million in cost of goods sold, the gross margin is 60%.


Highlights and Quick Summary

  • Gross Margin for the quarter ending December 30, 2020 was 100.0% (a 0.0% decrease compared to previous quarter)
  • Year-over-year quarterly Gross Margin increased by Infinity%
  • Annual Gross Margin for 2020 was 0.0% (a NaN% decrease from previous year)
  • Annual Gross Margin for 2019 was 0.0% (a NaN% decrease from previous year)
  • Annual Gross Margin for 2018 was 0.0% (a -100.0% decrease from previous year)
  • Twelve month Gross Margin ending December 30, 2020 was 28.44% (a 148.82% increase compared to previous quarter)
  • Twelve month trailing Gross Margin increased by Infinity% year-over-year
Trailing Gross Margin for the last four month:
30 Dec '20 29 Sep '20 29 Jun '20 30 Mar '20
28.44% 11.43% 0.0% 0.0%
Visit stockrow.com/VTGN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Gross Margin of VistaGen Therapeutics, Inc.

Most recent Gross Marginof VTGN including historical data for past 10 years.

Interactive Chart of Gross Margin of VistaGen Therapeutics, Inc.

VistaGen Therapeutics, Inc. Gross Margin for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 100.0% 100.0% 0.0% 0.0% 0.0%
2019 0.0% 0.0%
2018 0.0%
2017 100.0%
2016 100.0% 0.0%
2013 100.0%
2012 100.0% 100.0% 100.0%
2011 100.0% 100.0% 100.0% 100.0% 100.0%
2010 100.0% 100.0%

Business Profile of VistaGen Therapeutics, Inc.

Sector: Healthcare
Industry: Biotechnology
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic, and others. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license and option agreements with Pherin Pharmaceuticals, Inc.; license and collaboration agreement with EverInsight Therapeutics Inc.; and license and sublicense agreement with BlueRock Therapeutics, LP. The company was founded in 1998 and is headquartered in South San Francisco, California.